STADA Arzneimittel, the parent company of Thornton & Ross (T&R) and Reading-based Britannia Pharmaceuticals, has strengthened its footprint in specialty pharmaceuticals by acquiring an innovative therapy used for treating late-stage Parkinson’s disease.
The infusion of levodopa, carbidopa and entacapone is already approved in Sweden, Denmark, Norway and Finland, and STADA is currently submitting approval applications to launch the therapy in a number of major European markets.
German-headquartered STADA is increasingly adding differentiated specialty pharmaceuticals to its existing strengths in generics and non-prescription consumer health products.
STADA’s Britannia, which is headquartered in Reading, focuses on neurology and central nervous system indications, already offers apomorphine hydrochloride injection and infusion treatments. The deal also reflects STADA’s ongoing commitment to supplying patient-focused value-added medicines, including in central nervous system indications.
STADA CEO Peter Goldschmidt comments: “This acquisition of Lobsor significantly expands STADA’s specialty footprint and serves as further evidence that STADA is a leading go-to-partner for specialty pharmaceuticals, generics and consumer health products.
“It also complements our portfolio and expertise in the treatment of late-stage Parkinson’s disease, where we have strong expertise via our company Britannia Pharmaceuticals.”
Robert Wood, Managing Director of Britannia, comments: “We believe this infusion formulation will have positive clinical benefits for patients who need a device-aided, continuous form of therapy which can resolve intractable motor fluctuations and improve their quality of life.
“We aim to broaden patient access to a device that is light, user-friendly, and discreet, enabling them to get on with their everyday lives with the full support of Britannia’s existing 24-hour Parkinson’s disease nurse service.”